Newer oral agents with activity in GVHD may be better tolerated in older patients (e.g., Janus kinase/JAK or Bruton’s tyrosine kinase/BTK inhibitors), but these have not been systematically studied in older patients [83,84,85]. The gene discussed is BTK; the disease is graft versus host disease.